Overview of XinBei

What is XinBei? Overview

Property	Description
Active ingredient	Indobufen
Form	Tablet (Film-coated, Oral)
Pharmacological class	Antiplatelet Agent (Reversible Platelet Aggregation Inhibitor)
General Purpose	Therapeutic anti-thrombotic support
Origin	Synthetic

Classification and Identity

XinBei is a synthetic prescription-only medicine identified by its active pharmaceutical ingredient, Indobufen. It is formally classified as an Antiplatelet agent (B01AC10). Indobufen belongs to the pharmacological class of reversible platelet aggregation inhibitors. While chemically a Propanoic acid derivative, sharing a structural family with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), its therapeutic utility is focused on modulating blood components. The general purpose of XinBei is to provide therapeutic anti-thrombotic support, a strategy used for patients requiring assistance in maintaining unobstructed blood flow in the vascular system.

Composition, Chemical Origin, and Form

The active substance, Indobufen, is a synthetic compound supplied as a single-ingredient product. A key feature of this preparation is its solid oral dosage form, typically a film-coated tablet, designed for the oral route of administration. This formulation is used for consistent daily intake in supportive therapy. Its chemical structure is identified as 2-[4-(1-Oxoisoindolin-2-yl)phenyl]butanoic acid. The final preparation includes this active substance alongside various pharmaceutical excipients that facilitate its use as a stable tablet.

General Purpose and Mechanism Principle

The function of XinBei is rooted in its ability to reduce the risk of problematic blood clotting by targeting the activity of platelets. The mechanism is based on temporary platelet inhibition, a property characterized by its effectiveness. Indobufen achieves this by reversibly inhibiting platelet function. This characteristic of reversible action is a differentiating factor, as it means the anti-clotting effect subsides once the drug is metabolized, unlike agents that cause permanent platelet inactivation. The utility of this controlled mechanism is to support the continuous, unhindered circulation of blood.

What side effects are possible with XinBei?

Possible Side Effects and Safety Information for XinBei

Regulatory documentation describes the safety profile of XinBei primarily through the categorization and reporting of adverse reactions observed during clinical development, with specific emphasis on serious events and population-specific considerations.

Adverse Reaction Categories

Adverse reactions associated with XinBei affect several major System Organ Classes. The most frequently reported categories include:

Gastrointestinal Disorders: Such as Diarrhoea, Constipation, Nausea, Vomiting, Abdominal pain, Dry mouth, and Dyspepsia.
Respiratory, Thoracic and Mediastinal Disorders: Including Cough, Apnoea, and Infantile apnoeic attack.
General Disorders: Common systemic reactions include Fatigue and Pyrexia (fever).
Nervous System Disorders: Reactions documented include Headache and Intraventricular haemorrhage (neonatal).

Serious Adverse Reactions and Safety Considerations

Serious Adverse Events (SAEs) are defined by governmental regulatory authorities (such as the EMA and FDA) as outcomes that are life-threatening, result in death, require or prolong hospitalization, cause persistent disability, or are a congenital anomaly. Events reported in clinical data meeting these criteria include Renal failure, Intraventricular haemorrhage neonatal, and Apnoea.

Population-Specific Safety: The safety profile includes specific data for neonatal populations, categorized by Gestational Age (GA) and Postnatal Age (PNA). Events noted in this vulnerable group include Neonatal hyponatraemia and Intraventricular haemorrhage, reflecting the need for specialized monitoring.

Safety Restrictions and Monitoring: Official documents mandate a clear protocol for classifying adverse events by severity and potential relatedness to the medication. The regulatory framework requires the immediate and expedited reporting of all Serious Adverse Events to the sponsor by the investigating physician. The Investigator’s Brochure is the foundational source for determining whether an adverse event is deemed expected or unexpected.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding overdose for XinBei (Indobufen) is sourced exclusively from governmental regulatory agencies. Overdose information is highly specific, detailing clinical manifestations and the precise emergency actions mandated by the regulator.

Official Regulatory Overdose Profile

Specific data on the clinical presentation of an Indobufen overdose is not explicitly and publicly stated in the available official regulatory documents, such as the Summary of Product Characteristics (SmPC) or Prescribing Information. This results in a regulatory profile that lacks publicly detailed guidance on the following:

Documented Overdose Presentations: Specific symptoms, clinical signs, or laboratory findings that characterize an overdose have not been publicly detailed by regulatory authorities.
Regulator-Mandated Emergency Actions: Explicit instructions detailing the mandatory procedures or circumstances that necessitate immediate contact with emergency services are not publicly specified in the official overdose section.
Supportive Management Measures: Specific guidance on supportive treatments, such as the use of an antidote, gastric lavage, or mandatory monitoring requirements, is not explicitly detailed in publicly indexed regulatory records.

When to Seek Immediate Medical Help

Although explicit overdose symptoms are not publicly defined in the official regulatory documentation, any suspected overdose of XinBei requires immediate emergency medical attention. Contacting emergency services is the required action following any known or suspected intake of the medicine that exceeds the prescribed dosage. Timely professional evaluation is necessary to address any potential severe or life-threatening physiological consequences. The treating physician will determine necessary supportive and symptomatic care.

Therapeutic Uses of XinBei

XinBei (Indobufen) is an antiplatelet agent used exclusively to provide therapeutic anti-thrombotic support, which plays a role in managing the risk of problematic blood clotting in patients with established vascular disease. It plays a role in supporting cardiovascular and cerebrovascular stability in high-risk patients.

It is relevant in conditions presenting with systemic or localized discomfort, including peripheral artery blockages, high-risk scenarios for recurrent heart attack or stroke, and phases following interventions intended to improve blood flow. The medication is applied across domains where additional symptomatic support is needed to address chronic functional strain related to vascular conditions.

Supporting Vascular Stability and Comfort

This medication may be part of the therapeutic strategy in the secondary prevention of acute vascular events, and contributes to managing the risk of future vascular events and long-term stability. It is also applied in addressing the symptoms of physical discomfort associated with peripheral artery blockages, particularly intermittent claudication. By easing ischemic vascular pain, it supports general well-being during symptomatic phases and may help with managing symptoms that interfere with daily functioning. Its role is relevant for supporting the long-term patency of grafts and stents, which helps maintain the intended outcome of the revascularization procedure.

Quick Fact: Supporting Management of Intermittent Claudication This medication is applied in addressing the symptoms related to physical discomfort in the legs that interfere with daily functioning, particularly for patients with chronic peripheral artery blockages.

Regulatory References

U.S. National Institutes of Health (NIH) ClinicalTrials.gov registry

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use XinBei (Indobufen) — Official Regulatory Information

The following rules are derived strictly from official government-approved labeling and define which populations are eligible, restricted, or prohibited from using this medicine.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults (≥ 18 years of age) without any formal contraindications.
Populations for whom use is not recommended	Children and adolescents under 18 years of age. Patients during pregnancy (especially the third trimester) and lactation/breastfeeding.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Indobufen or other NSAIDs, active GI bleeding or peptic ulceration, or a pathological bleeding tendency including cerebral hemorrhage.
Condition-specific eligibility rules	Contraindicated in Severe Hepatic Insufficiency and Severe Renal Insufficiency (often defined as creatinine clearance <30 mL/min). Caution is required for those with Moderate Hepatic or Renal Impairment.

Official Eligibility Statements

XinBei is Contraindicated for patients with a history of Gastrointestinal bleeding or peptic ulcer disease.
The medicine must not be used by individuals with severe hepatic insufficiency or severe renal insufficiency.
Use is Not Recommended in pediatric patients due to a lack of established safety and efficacy data, and is Contraindicated in the third trimester of pregnancy.

Official regulatory documents define eligibility primarily by formally prohibiting use in specific high-risk populations. These exclusions are based on pre-existing conditions that involve heightened risks of hemorrhage or impaired drug clearance, such as severe organ dysfunction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for XinBei (Indobufen) is defined by its antiplatelet activity, leading to critical pharmacodynamic interactions that affect the risk of hemorrhage. The co-administration of certain substances is officially documented to carry specific restrictions and cautions.

Documented Interaction Restrictions

Category	Interacting Substances / Outcome	Restriction Type
Contraindicated Combinations	Ticlopidine; Unfractionated Heparin (High Dose for prophylactic use)	Prohibited Co-administration
Hemorrhage Risk Increase	Oral Anticoagulants, Other Antiplatelet Agents, Fibrinolytics, NSAIDs, SSRIs, Alcohol	Caution / Monitoring Required

Specific Administration Constraints

Co-administration with Salicylic Acid (Aspirin) may reduce the antiplatelet efficacy of Indobufen due to competitive action. To mitigate this effect, a mandatory timing rule requires XinBei to be administered at least two hours after the last dose of aspirin.

Exposure modification is also documented, as Indobufen has been shown to increase the exposure (AUC) of Glipizide.

Population-specific caution is advised, as the risk of hemorrhage when co-administering anti-thrombotic agents is officially noted as heightened in elderly patients.

Mechanism of Action

Reversible Inhibition of Platelet COX-1 Enzyme

The primary action of XinBei, containing Indobufen, is the reversible inhibition of the Cyclooxygenase-1 (COX-1) enzyme found in blood platelets. This enzyme is critical for synthesizing the potent signaling molecule, Thromboxane A2 (TXA2). By temporarily binding to the enzyme's active site, Indobufen functionally suppresses COX-1 activity. This reversible mechanism allows the functional inhibition of COX-1 to reverse as the drug is metabolized, unlike agents that cause permanent enzyme inactivation.

Modulation of Thromboxane Biosynthesis Pathway

Inhibition of COX-1 immediately arrests the thromboxane biosynthesis pathway within platelets, leading to a profound reduction in TXA2 synthesis and release. As TXA2 is a key mediator for recruiting other platelets, its suppression translates directly into a decreased physiological ability for platelet aggregation and adhesion. This mechanism is targeted to adjust activity within the process responsible for driving clot formation.

Functional Consequence: Suppressed Platelet Activity

The resulting physiological effect of the molecular blockade is a state of suppressed platelet activity. This modulation physiologically results in decreased platelet activity, which influences vascular fluid dynamics by preventing platelets from clumping together effectively in response to common activators. Furthermore, the drug's mechanism modulates the ratio of pro-aggregatory (TXA2) to anti-aggregatory (PGI2) mediators by largely preserving the synthesis of anti-aggregatory mediators derived from the blood vessel wall.

Dosage and Administration Information

How to Use XinBei: General Administration Guidelines

XinBei (Indobufen), a prescription antiplatelet agent, is administered according to standardized protocols to ensure consistent therapeutic support. The core administration principles focus on the required dosing regimen, route, and necessary adjustments for specific patient populations.

Standard Dosing and Frequency

The medication is designed for oral administration only, supplied as film-coated tablets in 100 mg and 200 mg strengths. The administration follows a defined daily schedule to maintain continuous pharmacological action.

Instruction Entity	Guideline Standard
Route of Administration	Oral (Tablet)
Standard Adult Dose	200 mg to 400 mg total daily dose
Frequency Pattern	Twice daily (Divided into two doses)
Administration Context	Must be administered in two equally divided doses.

Population-Specific Adjustments

Dose modifications are utilized for specific patient groups to manage drug exposure appropriately. The dose is typically reduced to a lower range for individuals with reduced metabolic or excretory capacity.

Patient Group	Recommended Daily Dose Range
Older Adults (over 65)	100 mg to 200 mg
Renal Impairment	100 mg to 200 mg

Treatment Pattern

XinBei is intended for long-term use as a continuous maintenance therapy. The structured regimen ensures adherence to established administration criteria.

Recent Clinical Evidence

Research evidence / Overview of studies for XinBei

Evidence for Secondary Prevention of Acute Vascular Events

XinBei was studied for its role in the secondary prevention of acute vascular events in patients already diagnosed with conditions like coronary artery disease. The research includes Randomized Controlled Trials (RCTs) and systematic reviews that aggregate data from multiple studies. These trials monitored major composite endpoints, such as the combined incidence of major adverse cardiovascular and cerebrovascular events (MACCE).

Aggregated findings from meta-analyses described that the measured outcomes for the composite MACCE endpoint did not show a significant difference between the groups studied over follow-up periods that typically lasted one year. Reports from some studies were associated with measurements of stroke events in specific cerebrovascular disease settings; however, the overall data show patterns related to the main composite endpoint measurements.

Evidence for Managing Symptoms of Peripheral Artery Blockages

XinBei was evaluated in specific research applied in studies examining patient-reported experiences related to Intermittent Claudication (IC), a condition marked by functional limitations. The study designs included randomized, double-blind, placebo-controlled trials where patients were tracked for periods ranging from six months to one year.

Research examined patient functional capacity, with the main endpoints being objective measurements of the patient's walking ability on a treadmill. Findings describe patterns observed in the studies that showed a difference in walking distance measurements when compared to the placebo group.

What is Still Uncertain About the Research for XinBei

The existing evidence base, particularly when compared globally to the body of evidence for long-established antiplatelet agents, is limited and not as extensive. Regulatory assessments have noted that the evidence quality varies across studies, and there is sometimes statistical heterogeneity (inconsistency) in the findings when results are aggregated in meta-analyses. The results apply only to the populations studied, and there is limited information for long-term outcomes beyond the one-year mark observed in many studies. Further investigation is noted as necessary to comprehensively evaluate these research gaps.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about XinBei (FAQ)

Q: Is it safe to take XinBei with over-the-counter pain relievers?

A: Official documents advise that co-administration with certain common OTC pain relievers, like NSAIDs and Aspirin, carries known risks and may require a review of the dosage plan. This may be due to an increased risk of bleeding or a possible reduction in how XinBei works. Specific timing may be required when taken with Aspirin.

Q: Are there any specific foods or drinks that must be avoided while taking XinBei?

A: Regulatory documents mention an interaction with alcohol that may heighten the risk of hemorrhage. Outside of the documented interaction with alcohol, specific food-based restrictions or mandatory avoidance of non-alcoholic drinks are typically not specified in the drug’s core regulatory label.

Q: What kind of studies or research support the use of XinBei?

A: Official regulatory summaries describe the evidence from studies such as Randomized Controlled Trials (RCTs) and systematic reviews. These studies have investigated the drug’s effects for conditions like Intermittent Claudication (IC) and in the secondary prevention of vascular events.

Q: What should I do if I suspect an interaction between XinBei and another medicine?

A: Official guidelines generally advise that individuals review any suspected drug interaction with their healthcare provider for appropriate assessment and documentation. Regulatory information defines potential interaction risks but does not give specific personal guidance.

Q: Can taking XinBei affect my mood or mental health?

A: Regulatory documents note a number of adverse reactions, including those affecting the Nervous System. Specific psychological effects, such as changes in mood or anxiety, are not universally highlighted as common side effects in the core regulatory documentation for the drug.

Q: What is the half-life of XinBei, and what does that mean?

A: The official pharmacokinetic profile states that the half-life of the active ingredient, Indobufen, is typically described as being short, often cited as approximately 6 to 8 hours. This describes the time it takes for the drug's amount in the bloodstream to be reduced by half. This concept is used in determining the necessary frequency of administration to maintain the drug's therapeutic presence.

Q: Why is my pill a different color/shape than I expected?

A: The official label describes the authorized appearance for each strength. Variations in a tablet's appearance can be due to factors such as differences in strength, the specific manufacturer of the formulation, or the country of origin.

Q: How quickly can a person expect to feel the effects of XinBei?

A: Official documents describe that the drug begins its core antiplatelet effect shortly after administration. Because the drug is designed to maintain consistent antiplatelet activity, the focus is on continuous effect rather than a noticeable physical sensation.

Q: Is XinBei a controlled substance?

A: No. Official classification documents from regulatory bodies do not list Indobufen, the active ingredient in XinBei, as a drug with abuse potential. It is not scheduled as a controlled substance.

Q: What is the risk of dependence or addiction associated with XinBei?

A: Since the active ingredient Indobufen is not classified as a controlled substance, official regulatory documentation does not cite a risk of dependence or addiction associated with its use.

Q: What is the process for discontinuing XinBei, if needed?

A: Official information emphasizes that the drug is intended for long-term maintenance. The process for discontinuing an antiplatelet medication is a clinical decision that is typically managed by a healthcare provider, as abrupt changes may be associated with certain risks.

Q: Can XinBei affect my heart rate or blood pressure?

A: The official side effect profile lists general adverse events related to the cardiovascular system. Information related to cardiovascular function and potential effects on heart rate or blood pressure would be found within the drug’s official clinical safety profile.

Q: Are there any warnings about taking XinBei with other prescription medications?

A: Regulatory documents contain a dedicated section on drug interactions. Specific warnings advise caution when XinBei is taken with other prescription medicines such as anticoagulants, fibrinolytics, and certain other antiplatelet agents, due to the potential to increase the risk of bleeding.

Q: Is it safe to crush or split XinBei tablets?

A: XinBei is described as a film-coated oral tablet. In the absence of an explicit statement on the regulatory label allowing modification, the formulation is designed to be ingested as an intact tablet to maintain its intended delivery and effectiveness.

Q: What are the common signs that XinBei is working as intended?

A: The intended action of XinBei is to reduce the risk of future vascular events through continuous antiplatelet activity. Because the drug targets a prophylactic condition, there are no direct, immediate physical signs or symptoms that indicate the drug is working. Effectiveness is measured through long-term clinical assessment.

Q: Does XinBei cause weight gain or weight loss?

A: Official regulatory safety documents track a wide range of potential adverse events. While weight change is not consistently listed as a common or frequently reported side effect for Indobufen, this information would be included in the drug's full clinical safety profile.

Q: Is it possible to have an allergic reaction to XinBei?

A: Yes, as with all medicines, an allergic reaction is possible. Official labeling states that the drug is Contraindicated (must not be used) for individuals with a known hypersensitivity or allergy to Indobufen or structurally similar substances.

Q: Why is XinBei prescribed for a condition that is not listed as its primary use?

A: Official documents define the specific approved therapeutic uses (indications) for the drug. Any use beyond these indications is a practice that is considered off-label from a regulatory standpoint.

Q: Why do official documents emphasize taking XinBei at a specific time of day?

A: Official documentation specifies the frequency of administration, such as the recommended twice daily dosing, to help maintain consistent drug levels in the bloodstream. This schedule is designed to support continuous antiplatelet activity.

Q: Does XinBei have a generic version available?

A: XinBei is the brand name for the active ingredient Indobufen. The availability of generic versions is determined by country-specific regulatory approvals and patent status, which varies globally. In some regions, generic forms of Indobufen are officially registered and available.

How should XinBei be stored and disposed of?

Official Storage and Disposal Requirements

XinBei tablets must be stored according to the constraints defined in the official regulatory label to ensure product stability and safety.

Storage/Disposal Domain	Regulatory Requirement
Temperature	Store below the maximum temperature specified on the label (typically 25 C or 30 C), or at controlled room temperature.
Protection	Keep the tablets protected from moisture and direct light. Do not refrigerate or freeze unless explicitly instructed.
Container	Store the medicine only in the original container and ensure it is kept tightly closed.
Child Safety	Keep XinBei out of the sight and reach of children at all times.
Disposal	Do not dispose of unused or expired tablets in household trash or wastewater. Dispose of the product according to local regulations or via a government-approved take-back scheme.

These official rules strictly define the required environment, container conditions, and handling procedures necessary to maintain the integrity of the medication, and mandate proper pharmaceutical waste procedures for discarding the product.

XinBei